Skip to main content
Top
Published in: Pain and Therapy 1/2018

Open Access 01-06-2018 | Review

A Brief History of the Opioid Epidemic and Strategies for Pain Medicine

Authors: Mark R. Jones, Omar Viswanath, Jacquelin Peck, Alan D. Kaye, Jatinder S. Gill, Thomas T. Simopoulos

Published in: Pain and Therapy | Issue 1/2018

Login to get access

Abstract

The opioid epidemic has resulted from myriad causes and will not be solved by any simple solution. Consequent to a staggering increase in opioid-related deaths in the USA, various governmental inputs and stakeholder strategies have been proposed and implemented with varying success. This article summarizes the history of opioid use and explores the causes for the present day epidemic. Recent trends in opioid-related data demonstrate an almost fourfold increase in overdose deaths from 1999 to 2008. Tragically, opioids claimed over 64,000 lives just last year. Some solutions have undergone legislation, including the limitation of numbers of opioids postsurgery, as well as growing national prevalence of enhanced recovery after surgery protocols which focus on reduced postoperative opioid consumption and shortened hospital stays. Stricter prescribing practices and prescription monitoring programs have been instituted in the recent past. Improvement in abuse deterrent strategies which is a major focus of the Food and Drug Administration (FDA) for all opioid preparations will likely play an important role by increasing the safety of these medications. Future potential strategies such as additional legislative policies, public awareness, and physician education are also detailed in this review.
Literature
1.
go back to reference Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff (Millwood). 2016;35:1876–83.CrossRef Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff (Millwood). 2016;35:1876–83.CrossRef
2.
4.
go back to reference Guy GP Jr, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(697–704):4. Guy GP Jr, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(697–704):4.
5.
go back to reference Ingraham C. CDC releases grim new opioid overdose figures: ‘We’re talking about more than an exponential increase.’ The Washington Post, December 21, 2017. Ingraham C. CDC releases grim new opioid overdose figures: ‘We’re talking about more than an exponential increase.’ The Washington Post, December 21, 2017.
7.
go back to reference Clarke JL, Skoufalos A, Scranton R. The American opioid epidemic: population health implications and potential solutions. Report from the National Stakeholder Panel. Popul Health Manag. 2016;19(1):1–10.CrossRef Clarke JL, Skoufalos A, Scranton R. The American opioid epidemic: population health implications and potential solutions. Report from the National Stakeholder Panel. Popul Health Manag. 2016;19(1):1–10.CrossRef
8.
go back to reference Meldrum ML, editor. Opioids and pain relief: a historical perspective. Seattle: International Association for the Study of Pain; 2003. Meldrum ML, editor. Opioids and pain relief: a historical perspective. Seattle: International Association for the Study of Pain; 2003.
9.
go back to reference Schiffrin MJ. The management of pain in cancer. St Louis: Year Book; 1956. p. 7–8. Schiffrin MJ. The management of pain in cancer. St Louis: Year Book; 1956. p. 7–8.
10.
go back to reference Morgan JP. American opiophobia: customary underutilization of opioid analgesics. Adv Alcohol Subst Abuse. 1985;5:163–73.CrossRefPubMed Morgan JP. American opiophobia: customary underutilization of opioid analgesics. Adv Alcohol Subst Abuse. 1985;5:163–73.CrossRefPubMed
11.
go back to reference Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet. 1993;341(8852):1075–6.CrossRefPubMed Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet. 1993;341(8852):1075–6.CrossRefPubMed
12.
go back to reference Marks RM, Sachar EJ. Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med. 1973;78(2):173–81.CrossRefPubMed Marks RM, Sachar EJ. Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med. 1973;78(2):173–81.CrossRefPubMed
13.
go back to reference Max MB. Improving outcomes of analgesic treatment: is education enough? Ann Intern Med. 1990;113(11):885–9.CrossRefPubMed Max MB. Improving outcomes of analgesic treatment: is education enough? Ann Intern Med. 1990;113(11):885–9.CrossRefPubMed
14.
go back to reference Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302(2):123.PubMed Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302(2):123.PubMed
15.
go back to reference Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25(2):171–86.CrossRefPubMed Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25(2):171–86.CrossRefPubMed
16.
go back to reference WHO. Cancer pain relief. Geneva: WHO; 1986. WHO. Cancer pain relief. Geneva: WHO; 1986.
19.
20.
21.
go back to reference Mularski RA, White-Chu F, Overbay D, Miller L, Asch SM, Ganzini L. Measuring pain as the 5th vital sign does not improve quality of pain management. J Gen Intern Med. 2006;21(6):607–12.CrossRefPubMedPubMedCentral Mularski RA, White-Chu F, Overbay D, Miller L, Asch SM, Ganzini L. Measuring pain as the 5th vital sign does not improve quality of pain management. J Gen Intern Med. 2006;21(6):607–12.CrossRefPubMedPubMedCentral
22.
go back to reference Baker DW. History of the Joint Commission’s pain standards: lessons for today’s prescription opioid epidemic. JAMA. 2017;317(11):1117–8.CrossRefPubMed Baker DW. History of the Joint Commission’s pain standards: lessons for today’s prescription opioid epidemic. JAMA. 2017;317(11):1117–8.CrossRefPubMed
23.
go back to reference Joranson DE, Gilson AM, Dahl JL, Haddox JD. Pain management, controlled substances, and state medical board policy: a decade of change. J Pain Symp Manag. 2002;23(2):138–47.CrossRef Joranson DE, Gilson AM, Dahl JL, Haddox JD. Pain management, controlled substances, and state medical board policy: a decade of change. J Pain Symp Manag. 2002;23(2):138–47.CrossRef
24.
go back to reference Fenton JJ, Jerant AF, Bertakis KD, Franks P. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med. 2012;172(5):405–11.CrossRefPubMed Fenton JJ, Jerant AF, Bertakis KD, Franks P. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med. 2012;172(5):405–11.CrossRefPubMed
25.
go back to reference Tucker KL. Medico-legal case report and commentary: inadequate pain management in the context of terminal cancer. The case of Lester Tomlinson. Pain Med. 2004;5:214–28.CrossRefPubMed Tucker KL. Medico-legal case report and commentary: inadequate pain management in the context of terminal cancer. The case of Lester Tomlinson. Pain Med. 2004;5:214–28.CrossRefPubMed
26.
go back to reference Hwang CS, Chang HY, Alexander GC. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiol Drug Saf. 2015;24(2):197–204.CrossRefPubMed Hwang CS, Chang HY, Alexander GC. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiol Drug Saf. 2015;24(2):197–204.CrossRefPubMed
27.
go back to reference Manchikanti L, Kaye AM, Knezevic N, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017;20(2S):S3–92.PubMed Manchikanti L, Kaye AM, Knezevic N, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017;20(2S):S3–92.PubMed
28.
go back to reference Frasco PE, Sprung J, Trentman TL. The impact of the Joint Commission for Accreditation of Healthcare Organizations pain initiative on perioperative opiate consumption and recovery room length of stay. Anesth Analg. 2005;100(1):162–8.CrossRefPubMed Frasco PE, Sprung J, Trentman TL. The impact of the Joint Commission for Accreditation of Healthcare Organizations pain initiative on perioperative opiate consumption and recovery room length of stay. Anesth Analg. 2005;100(1):162–8.CrossRefPubMed
29.
go back to reference Vila H Jr, Smith RA, Augustyniak MJ, et al. The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: is patient safety compromised by treatment based solely on numerical pain ratings? Anesth Analg. 2005;101(2):474–80.CrossRefPubMed Vila H Jr, Smith RA, Augustyniak MJ, et al. The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: is patient safety compromised by treatment based solely on numerical pain ratings? Anesth Analg. 2005;101(2):474–80.CrossRefPubMed
33.
go back to reference Gudin J. Oxycodone DETERx®: a novel abuse-deterrent, extended-release analgesic option for the treatment of patients with chronic pain. Pain Ther. 2016;5(2):171–86.CrossRefPubMedPubMedCentral Gudin J. Oxycodone DETERx®: a novel abuse-deterrent, extended-release analgesic option for the treatment of patients with chronic pain. Pain Ther. 2016;5(2):171–86.CrossRefPubMedPubMedCentral
35.
go back to reference DePriest AZ, Miller K. Oxycodone/naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther. 2014;3(1):1–15.CrossRefPubMedPubMedCentral DePriest AZ, Miller K. Oxycodone/naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther. 2014;3(1):1–15.CrossRefPubMedPubMedCentral
36.
go back to reference Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16(11):2142–51.CrossRefPubMed Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16(11):2142–51.CrossRefPubMed
37.
go back to reference Jones MR, Carney MJ, Kaye RJ, Prabhakar A, Kaye AD. Drug formulation advances in extended-release medications for pain control. Curr Pain Headache Rep. 2016;20:36.CrossRefPubMed Jones MR, Carney MJ, Kaye RJ, Prabhakar A, Kaye AD. Drug formulation advances in extended-release medications for pain control. Curr Pain Headache Rep. 2016;20:36.CrossRefPubMed
38.
go back to reference Pergolizzi J, Taylor R, LeQuang J, Raffa R. Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. J Pain Res. 2018;11:301–11.CrossRefPubMedPubMedCentral Pergolizzi J, Taylor R, LeQuang J, Raffa R. Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. J Pain Res. 2018;11:301–11.CrossRefPubMedPubMedCentral
41.
go back to reference “Affordable Care Act.” Managed and paid for by the U.S. Centers for Medicare and Medicaid Services, healthcare.gov. “Affordable Care Act.” Managed and paid for by the U.S. Centers for Medicare and Medicaid Services, healthcare.gov.
43.
go back to reference Krawczyk N, Negron T, Nieto M, Agus D, Fingerhood M. Overcoming medication stigma in peer recovery: a new paradigm. Subs Abus. 2018;12:10. Krawczyk N, Negron T, Nieto M, Agus D, Fingerhood M. Overcoming medication stigma in peer recovery: a new paradigm. Subs Abus. 2018;12:10.
45.
go back to reference Wen L, Warren K. Combating the opioid epidemic: Baltimore’s experience and lessons learned. J Public Health (Oxf). 2017;19:1–5. Wen L, Warren K. Combating the opioid epidemic: Baltimore’s experience and lessons learned. J Public Health (Oxf). 2017;19:1–5.
47.
48.
go back to reference Manchikanti L, Soin A, Mann DP, et al. Reversal of growth of utilization of interventional techniques in managing chronic pain in Medicare population post Affordable Care Act. Pain Phys. 2017;20:551–67. Manchikanti L, Soin A, Mann DP, et al. Reversal of growth of utilization of interventional techniques in managing chronic pain in Medicare population post Affordable Care Act. Pain Phys. 2017;20:551–67.
49.
go back to reference Auriacombe M, Fatséas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict. 2004;13:S17–28.CrossRefPubMed Auriacombe M, Fatséas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict. 2004;13:S17–28.CrossRefPubMed
Metadata
Title
A Brief History of the Opioid Epidemic and Strategies for Pain Medicine
Authors
Mark R. Jones
Omar Viswanath
Jacquelin Peck
Alan D. Kaye
Jatinder S. Gill
Thomas T. Simopoulos
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 1/2018
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-018-0097-6

Other articles of this Issue 1/2018

Pain and Therapy 1/2018 Go to the issue